BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
32997133
Number of visits today
744
Number of downloads
16182932
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Zhu YG, Xiao BF, Zhang JT, Cui XR, Lu ZM, Wu N. Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application. Front Oncol 2021;11:763806. [PMID: 34858843 DOI: 10.3389/fonc.2021.763806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang K, Zhao Y, Sun G, Zhang X, Cao J, Shao M, Liang X, Wang L. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1081546] [Reference Citation Analysis]
2 Wang H, Xu Y, Zuo F, Liu J, Yang J. Immune-based combination therapy for esophageal cancer. Front Immunol 2022;13:1020290. [PMID: 36591219 DOI: 10.3389/fimmu.2022.1020290] [Reference Citation Analysis]
3 Zhang Z, Leng Z, Fang K, Sun M, Li Z, Kang L, Chen T, Xu M. Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis. Front Oncol 2022;12:977935. [DOI: 10.3389/fonc.2022.977935] [Reference Citation Analysis]
4 Chen L, Chen F, Niu H, Li J, Pu Y, Yang C, Wang Y, Huang R, Li K, Lei Y, Huang Y. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Front Immunol 2022;13:871661. [DOI: 10.3389/fimmu.2022.871661] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345